Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Immunotherapy and Radiation in Resected Stage II/IIIA NSCLC
NCT00006470Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Mar 2001
- Primary completion
- Dec 2004
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of 11D10 anti-idiotype, 3H1 in non-small cell lung cancer (NSCLC), sponsored by NRG Oncology. Started Mar 2001; status: completed.
02
Drugs
11D10 anti-idiotype3H1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00006470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006470.